Scientific Presentations Scientific Presentations ACAAI Poster 2024 EPI 18 Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB ACAAI Poster 2024 PK Profiles Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB ACAAI Poster 2024 HCP interest in neffy Healthcare Professionals Interest in neffy: A Self–Administered Epinephrine Nasal Spray Device 1.1 MB ACAAI Poster 2024 BP Increase Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB ACCAI Poster 2024 EPI 10 JP03 neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB ACAAI Poster 2024 BP Safety Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration 831.2 KB AAAAI 2024 Phase 2 Urticaria Results ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Scientific Presentations ACAAI Poster 2024 EPI 18 Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB ACAAI Poster 2024 PK Profiles Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB ACAAI Poster 2024 HCP interest in neffy Healthcare Professionals Interest in neffy: A Self–Administered Epinephrine Nasal Spray Device 1.1 MB ACAAI Poster 2024 BP Increase Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB ACCAI Poster 2024 EPI 10 JP03 neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB ACAAI Poster 2024 BP Safety Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration 831.2 KB AAAAI 2024 Phase 2 Urticaria Results ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB
Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB
Healthcare Professionals Interest in neffy: A Self–Administered Epinephrine Nasal Spray Device 1.1 MB
Blood Pressure and Pulse Rate Increases Without Concomitant Epinephrine Increases During Acute Allergic Reactions 683.1 KB
neffy, Epinephrine Nasal Spray, Development, from Pharmacokinetics and Pharmacodynamics to Real-World Data in Pediatric Food Allergy Patients 905.4 KB
Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB
ARS-2 (neffy), Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results 567.4 KB
A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB